<code id='F6D1A2EBB0'></code><style id='F6D1A2EBB0'></style>
    • <acronym id='F6D1A2EBB0'></acronym>
      <center id='F6D1A2EBB0'><center id='F6D1A2EBB0'><tfoot id='F6D1A2EBB0'></tfoot></center><abbr id='F6D1A2EBB0'><dir id='F6D1A2EBB0'><tfoot id='F6D1A2EBB0'></tfoot><noframes id='F6D1A2EBB0'>

    • <optgroup id='F6D1A2EBB0'><strike id='F6D1A2EBB0'><sup id='F6D1A2EBB0'></sup></strike><code id='F6D1A2EBB0'></code></optgroup>
        1. <b id='F6D1A2EBB0'><label id='F6D1A2EBB0'><select id='F6D1A2EBB0'><dt id='F6D1A2EBB0'><span id='F6D1A2EBB0'></span></dt></select></label></b><u id='F6D1A2EBB0'></u>
          <i id='F6D1A2EBB0'><strike id='F6D1A2EBB0'><tt id='F6D1A2EBB0'><pre id='F6D1A2EBB0'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:6743
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead
          Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

          HasPhRMAlostitsfangs?Are11th-hourchangesominousforclinicaltrials?Andwhat’snextinpainmedicine?Wecover

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Surprise medical billing ban raises prices elsewhere

          ANGELAWEISS/AFPviaGettyImagesWithoutquestion,thenewfederallawbanningsurprisebillingisachievingitsgoa